Results of severe sepsis treatment program using recombinant human activated protein C in Poland

Medical Science Monitor

Volumn 12, Issue 3, 2006, Pages

  Kübler, Andrzej ^a   Mayzner Zawadzka, Ewa ^b   Durek, Grazyna ^a   Gaszyński, Wojciech ^c   Karpel, Ewa ^d   Mikaszewska Sokolewicz, Małgorzata ^b   Majak, Paweł ^e  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e Department of Otolaryngology   (Poland)

Author keywords

Intensive care unit; Mortality; Recombinant human activated protein C; Septic shock; Severe sepsis

Indexed keywords

ANTIBIOTIC AGENT; DROTRECOGIN; HEPARIN; HYPERTENSIVE FACTOR; STEROID;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INDEPENDENT VARIABLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLAND; RISK; SEPSIS;

ADULT; ANTI-INFECTIVE AGENTS; APACHE; EVALUATION STUDIES; FEMALE; HEMORRHAGE; HUMANS; INTENSIVE CARE UNITS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLAND; POPULATION SURVEILLANCE; PROTEIN C; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME;

EID: 33644683771     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bone RC, Balk RA, Cerra FB et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest, 1992; 101: 1644-55
2. Cohen J: The immunopathogenesis of sepsis. Nature, 2002; 420: 885-91
3. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis, 2002; 34: 1084-93
4. Abraham E, Reinhart K, Opal S et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 2003; 290: 238-47
5. Warren BL, Eid A, Singer P et al: High-dose antithrombin III in severe sepsis. A randomised, controlled trial. JAMA, 2001; 286: 1869-78
6. Bernard GL, Vincent Jl, Laterre PF et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001; 344: 699-709
7. Abraham E, Laterre PF, Garg R et al: Drotrecogin alfa (activated) for adults with severe sepsis and low risk of death. N Engl J Med, 2005; 353: 1332-41
8. Kübler A, Durek G, Zamirowska A et al: Severe sepsis in Poland - results of internet surveillance of 1043 cases. Med Sci Monit, 2004, 10(11), CR635-CR641
9. Ely EW, Laterre PF, Angus DC et al: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med, 2003; 31: 12-19
10. Hillman K: Critical care without walls. Curr Op Crit Care, 2002; 8: 594-99
11. Gao F, Melody T, Daniels DF et al: The impact of compliance with 6 hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective, observational study. Crit Care, 2005; 9: R764-R770